Theresa Townley, MD
Internal Medicine · Omaha, NENPI 1699881177
Payments from drug & device makers
Across 89 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$236
- Amgen$222
- Johnson & Johnson$138
- Novo Nordisk$127
- Grifols USA, LLC$108
- Boehringer Ingelheim$99
- plus $636 from 20 others
What the payments were for
- Food & beverage$1,566100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $236 |
| Amgen | 13 | $222 |
| Johnson & Johnson(2 entities) | 8 | $138 |
| Novo Nordisk | 8 | $127 |
| Grifols USA, LLC | 5 | $108 |
| Boehringer Ingelheim | 7 | $99 |
| Abbott | 5 | $86 |
| Lilly USA, LLC | 5 | $81 |
| Merck | 2 | $64 |
| Pfizer | 3 | $61 |
| E.r. Squibb & Sons, L.L.C. | 4 | $58 |
| Mannkind Corporation | 2 | $34 |
| Shire North American Group Inc | 2 | $25 |
| Boston Scientific | 1 | $25 |
| Harmony Biosciences LLC | 1 | $24 |
| UCB, Inc. | 1 | $22 |
| Verona Pharma, Inc. | 1 | $22 |
| Insmed, Inc. | 1 | $19 |
| Medtronic | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Novartis | 1 | $13 |
| Insulet Corporation | 1 | $13 |
| Tandem Diabetes Care, Inc. | 1 | $12 |
| AbbVie | 1 | $12 |
How this compares
$1,566 in reported general payments places this provider in the 80th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 71 | $77,083 |
| OzempicSemaglutide | 64 | $76,712 |
| EliquisApixaban | 116 | $70,264 |
| TrulicityDulaglutide | 23 | $30,442 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $23,037 |
| FarxigaDapagliflozin Propanediol | 17 | $22,069 |
| JanuviaSitagliptin Phosphate | 29 | $16,478 |
| MounjaroTirzepatide | 15 | $15,906 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $15,515 |
| EntrestoSacubitril/Valsartan | 16 | $12,674 |
| GemtesaVibegron | 24 | $11,159 |
| MyrbetriqMirabegron | 22 | $10,840 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $9,599 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $7,927 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $7,034 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $99 | $77,08371 claims |
| Novo NordiskOzempic | $127 | $76,71264 claims |
| PfizerEliquis | $61 | $70,264116 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $81 | $46,34938 claims |
| AstraZenecaFarxiga, Symbicort | $236 | $31,66949 claims |
| MerckJanuvia, Janumet | $64 | $24,40543 claims |
| NovartisEntresto | $13 | $12,67416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Omaha
- Michael DunnOmaha$7.9M
- Joel MichalskiOmaha$1.6M
- Ariana BauerOmaha$1.5M
- David CrockettOmaha$821K
- Bryant EnglandOmaha$637K
- Adam BurdorfOmaha$313K
- Brian BoerOmaha$142K
- David JasperOmaha$128K
- Andrew RorieOmaha$61K
- Mohamed AhmedOmaha$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.